BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
Decision on EU marketing authorisation for this population expected by September 2024
GSK and Flagship to jointly fund up to $150 million upfront
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Subscribe To Our Newsletter & Stay Updated
